Table 2 Changes in LDLC and CVD risk from study entry to last follow up visit in 69 patients taking Alirocumab 75 mg every 2 weeks (n = 29), or Alirocumab 150 mg (n = 18) or Evolocumab 140 mg (n = 22) every 2 weeks (ALI-EVO)
|  | Alirocumab 75 mg every 2 weeks (n = 29) Mean ± SD, median follow-up length 49 ± 13, 49 weeks | ALI-EVO (n = 40) Mean ± SD, median 37 ± 12, 33 weeks | |||||
|---|---|---|---|---|---|---|---|
Variable measured | percentile | percentile | |||||
25th | 50th | 75th | 25th | 50th | 75th | ||
LDLC | Entry (mg/dl) | 99 | 115 | 143 | 136 | 165 | 196 |
Follow up (mg/dl) | 49 | 68 | 89 | 45 | 70 | 93 | |
Absolute change (mg/dl) | −26 | −43 | −81 | −73 | −91 | −122 | |
 P (paired Wilcoxon) | p < .0001 | p < .0001 | |||||
Percent change (%) | −22 | −39 | −62 | −49 | −59 | -68 | |
 P (Wilcoxon) | p < .0001 | p < .0001 | |||||
CVD risk for next 10Â years With AHA calculator | Entry (%) | 4.8 | 11.5 | 18.1 | 3.9 | 10.2 | 19.4 |
Follow up (%) | 4.4 | 7.3 | 14.2 | 2.2 | 5.5 | 15.5 | |
Absolute change | −0.1 | −1.2 | −6.9 | −0.6 | −2.4 | −4.8 | |
 P (paired Wilcoxon) | p = .0008 | p < .0001 | |||||
Percent change (%) | −2.2 | −19.9 | −34.4 | −12.8 | −27.8 | -50.5 | |
 P (Wilcoxon) | p = .0042 | p < .0001 | |||||
CVD risk for next 10Â years With NIH calculator | Entry (%) | 6.8 | 12.9 | 21.7 | 9.1 | 14.2 | 24.8 |
Follow up (%) | 2.1 | 5.1 | 8.3 | 1.4 | 3.6 | 8.5 | |
Absolute change | −4.3 | −6.9 | −16.9 | −5.0 | −10.1 | −18.8 | |
 P (paired Wilcoxon) | p < .0001 | p < .0001 | |||||
Percent change (%) | −52.2 | −67.4 | −80.4 | −56.1 | −77.8 | -85.4 | |
 P (Wilcoxon) | p < .0001 | p < .0001 | |||||